Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The proceeds from the financing will be used to advance Augustine’s lead candidate, AGT100216, into early-stage clinical trials for the treatment of CMT and CIPN.
Lead Product(s): AGT100216
Therapeutic Area: Neurology Product Name: AGT100216
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $18.5 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 26, 2024